Clinical Trial: Efficacy and Safety of Iparomlimab and Tuvonralimab Combined With Capecitabine Chemotherapy as Postoperative Adjuvant Therapy for Patients With Radically Resected Cholangiocarcinoma (China)

China, Sept. 7 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Iparomlimab and Tuvonralimab Combined With Capecitabine Chemotherapy as Postoperative Adjuvant Therapy for Patients With Radically Resected Cholangiocarcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131681

Registration Time: 2026/09/05

Type: Interventional study

Primary Sponsor: The second affiliated hospital of Zhejiang University school of medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=341316

Published by HT Digital Content Services with permission from Health Daily Digest....